ALK and non-small cell lung carcinoma: Overall, this study confirms the effectiveness of ALK TKIs in real-world practice and provides further evidence supporting the potential benefit of multiple lines of ALK TKI therapy on overall survival for patients with advanced ALK-positive NSCLC.